Bicycle Therapeutics (BCYC) Accounts Payables (2018 - 2026)

Bicycle Therapeutics has reported Accounts Payables for 9 years, with the latest figure at $6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables fell 46.25% year-over-year to $6.0 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (down 46.25% YoY), and the FY2025 full-year result was $9.7 million, down 38.78% from the prior year.
• Accounts Payables for Q1 2026 stood at $6.0 million, down from $9.7 million in the prior quarter.
• The five-year high for Accounts Payables was $18.3 million in Q2 2025, with the low at $2.8 million in Q1 2023.
• Historically, Accounts Payables has averaged $8.6 million across 5 years, with a median of $7.1 million in 2024.
• Annual changes were most pronounced in 2022 — Accounts Payables soared 301.51% — and 2026, when it tumbled 46.25%.
• Bicycle Therapeutics' Accounts Payables stood at $6.5 million in 2022, then surged by 101.64% to $13.0 million in 2023, then climbed by 21.02% to $15.8 million in 2024, then plunged by 38.78% to $9.7 million in 2025, then slumped by 38.26% to $6.0 million in 2026.
• The last three Accounts Payables figures came in at $6.0 million (Q1 2026), $9.7 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.